Fig. 3
From: DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms
Increased DCYTB expression in molecular subtypes with better outcome in cohort #1. DCYTB expression in each breast cancer molecular subtype of cohort #1. Luminal A, n = 252; Normal-like, n = 154; Luminal B, n = 136; Her2, n = 61; Basal, n = 104. * p ≤ 0.0028 vs LumA, ** p ≤ 2.8e-15 vs LumA and Normal-like cohorts, *** p ≤ 0.0027 vs all other cohorts. DCYTB duodenal cytochrome b